Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
ALAltimmune, Inc. logo

Altimmune, Inc. (ALT)

NASDAQ Global Market · Currency in USD
$2.12 ▼ -0.05 (-2.30%)
At close: Oct 23, 4:00 PM ET. Market closed.
$2.14 ▲ +0.02 (+0.94%)
After hours: Oct 23, 7:57 PM ET

Summary

Previous Close
$2.17
Open
$2.16
Day's Range
$2.06 – $2.17
52 Week Range
$2.06 – $6.44
Volume
2,599,076
Avg. Volume
4,340,382
Market Cap
$412.38M
Beta (5Y Monthly)
0.18
PE Ratio (TTM)
--
EPS (TTM)
-$0.49
Earnings Date
Nov 5, 2026
Forward Dividend & Yield
$3,492.00 (164,716.98%)
Ex-Dividend Date
Feb 6, 2017
1y Target Est
$10.00

Profile: Altimmune, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
57
CEO
Jerome Benedict Durso

Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic steatohepatitis (NASH).

Earnings

Next report: Thu, Nov 5, 2026
EPS estimate -$0.14 · Revenue est. $1.75K
DateEst.Actual
Aug 11, 2026-$0.14-$0.12Beat
May 13, 2026-$0.25-$0.18Beat
Mar 5, 2026-$0.25-$0.27Miss
Nov 6, 2025-$0.29-$0.21Beat
Aug 12, 2025-$0.32-$0.27Beat
May 13, 2025-$0.35-$0.26Beat

Analyst view

Consensus price target
$10.00 ▲ +371.7%
Range $10.00 – $10.00
Rating: Buy
Buy 80% · Hold 20% · Sell 0%

Get free alerts on ALT and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.